Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
INTRODUCTION: The objective of the study was to evaluate the functional and anatomical results of intravitreal aflibercept (IVA) in cases resistant to intravitreal bevacizumab (IVB)/ intravitreal ranibizumab (IVR) for exudative age-related macular degeneration (AMD). METHODS: Patients who did not h...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kare Publishing
2023-09-01
|
| Series: | Boğaziçi Tıp Dergisi |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=bmj&un=BMJ-18199 |
| _version_ | 1827783665975820288 |
|---|---|
| author | Neslihan Sevimli Abdulkadir Alış |
| author_facet | Neslihan Sevimli Abdulkadir Alış |
| author_sort | Neslihan Sevimli |
| collection | DOAJ |
| description | INTRODUCTION: The objective of the study was to evaluate the functional and anatomical results of intravitreal aflibercept (IVA) in cases resistant to intravitreal bevacizumab (IVB)/ intravitreal ranibizumab (IVR) for exudative age-related macular degeneration (AMD). METHODS: Patients who did not have an increase in best-corrected visual acuity (BCVA) or intraretinal fluid (IRF)/ subretinal fluid (SRF) fluid regression despite at least three doses of IVB/IVR. The files of the patients were scanned and central macular thickness (CMT), presence of IRF/SRF, and height of pigment epithelial detachment (PED) were recorded before IVA, after 3 months of loading IVA, and 1 year after IVA and compared. RESULTS: A total of 31 patients with a mean age of 74.2+-10.53 were included in the study. The mean BCVA, CMT, and PED heights before IVA were 0.52+-0.31 LogMAR, 301.10+-76.27 µm, and 130.81+-73.72 µm, respectively. After three doses of IVA loading, mean BCVA, CMT, and PED heights were 0.51+-0.28 LogMAR, 262.86+-69.74 µm, and 96.00+-57.66 µm, respectively. A significant decrease was found in CMT and PED height values compared to the results obtained before IVA (p=0.001 and p=0.006). In the 1- year of IVA, mean BCVA, CMT, and PED heights were 0.53+-0.33 LogMAR, 257.61+-92.05 µm and 95.61+-66.67 µm, respectively. There was a significant decrease in CMT and PED values compared to the values obtained before IVA treatment (p=0.004 and p=0.04). DISCUSSION AND CONCLUSION: In exudative AMD patients resistant to IVB/IVR treatment, improvement in anatomical results is observed in the short and long term, while functional success is not affected by switch therapy. |
| first_indexed | 2024-03-11T15:51:38Z |
| format | Article |
| id | doaj.art-24eff2c827984ec99816859bfe24fcb6 |
| institution | Directory Open Access Journal |
| issn | 2149-0287 |
| language | English |
| last_indexed | 2024-03-11T15:51:38Z |
| publishDate | 2023-09-01 |
| publisher | Kare Publishing |
| record_format | Article |
| series | Boğaziçi Tıp Dergisi |
| spelling | doaj.art-24eff2c827984ec99816859bfe24fcb62023-10-25T18:48:16ZengKare PublishingBoğaziçi Tıp Dergisi2149-02872023-09-0110317918410.14744/bmj.2023.18199BMJ-18199Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular DegenerationNeslihan Sevimli0Abdulkadir Alış1Department of Ophthalmology, Fatih Sultan Mehmet Training and Research Hospital, İstanbul, TürkiyeDepartment of Ophthalmology, Fatih Sultan Mehmet Training and Research Hospital, İstanbul, TürkiyeINTRODUCTION: The objective of the study was to evaluate the functional and anatomical results of intravitreal aflibercept (IVA) in cases resistant to intravitreal bevacizumab (IVB)/ intravitreal ranibizumab (IVR) for exudative age-related macular degeneration (AMD). METHODS: Patients who did not have an increase in best-corrected visual acuity (BCVA) or intraretinal fluid (IRF)/ subretinal fluid (SRF) fluid regression despite at least three doses of IVB/IVR. The files of the patients were scanned and central macular thickness (CMT), presence of IRF/SRF, and height of pigment epithelial detachment (PED) were recorded before IVA, after 3 months of loading IVA, and 1 year after IVA and compared. RESULTS: A total of 31 patients with a mean age of 74.2+-10.53 were included in the study. The mean BCVA, CMT, and PED heights before IVA were 0.52+-0.31 LogMAR, 301.10+-76.27 µm, and 130.81+-73.72 µm, respectively. After three doses of IVA loading, mean BCVA, CMT, and PED heights were 0.51+-0.28 LogMAR, 262.86+-69.74 µm, and 96.00+-57.66 µm, respectively. A significant decrease was found in CMT and PED height values compared to the results obtained before IVA (p=0.001 and p=0.006). In the 1- year of IVA, mean BCVA, CMT, and PED heights were 0.53+-0.33 LogMAR, 257.61+-92.05 µm and 95.61+-66.67 µm, respectively. There was a significant decrease in CMT and PED values compared to the values obtained before IVA treatment (p=0.004 and p=0.04). DISCUSSION AND CONCLUSION: In exudative AMD patients resistant to IVB/IVR treatment, improvement in anatomical results is observed in the short and long term, while functional success is not affected by switch therapy.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=bmj&un=BMJ-18199afliberceptage-related macular degenerationbevacizumabranibizumab. |
| spellingShingle | Neslihan Sevimli Abdulkadir Alış Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration Boğaziçi Tıp Dergisi aflibercept age-related macular degeneration bevacizumab ranibizumab. |
| title | Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration |
| title_full | Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration |
| title_fullStr | Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration |
| title_full_unstemmed | Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration |
| title_short | Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration |
| title_sort | intravitreal aflibercept therapy in intravitreal bevacizumab ranibizumab treatment resistant exudative age related macular degeneration |
| topic | aflibercept age-related macular degeneration bevacizumab ranibizumab. |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=bmj&un=BMJ-18199 |
| work_keys_str_mv | AT neslihansevimli intravitrealaflibercepttherapyinintravitrealbevacizumabranibizumabtreatmentresistantexudativeagerelatedmaculardegeneration AT abdulkadiralıs intravitrealaflibercepttherapyinintravitrealbevacizumabranibizumabtreatmentresistantexudativeagerelatedmaculardegeneration |